NDRG2 inhibits hepatocellular carcinoma adhesion, migration and invasion by regulating CD24 expression
Jin Zheng(Shanghai University of Traditional Chinese Medicine), Wenchao Liu(University of Chicago), Heng-jun Shi(Tang Du Hospital), Yurong Tao, Ming Shi(Yanshan University), Libo Yao(Civil Aviation University of China), Qiang Liu(Sun Yat-sen University), Rui Zhang(Air Force Medical University), Hang Guo(Second Affiliated Hospital of Jilin University), Yan Li(The University of Texas Southwestern Medical Center), Jiandong Yang(National Institute on Aging), Ji Ma(Northwest A&F University), Xue Yan(Wuhan University), Ning Jiang(University of California, Los Angeles), Qinyou Ren(Tang Du Hospital)
Cited by 90
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc
|Nature Communications|2019|434
RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming
|Nature Communications|2021|414